CLASS ACTION UPDATE for FSCT, GERN and WBK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / February 21, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

FSCT Shareholders Click Here: https://www.zlk.com/pslra-1/forescout-technologies-inc-loss-form?prid=5501&wire=1
GERN Shareholders Click Here: https://www.zlk.com/pslra-1/geron-corporation-et-al-loss-form?prid=5501&wire=1
WBK Shareholders Click Here: https://www.zlk.com/pslra-1/westpac-banking-corporation-loss-form?prid=5501&wire=1

* ADDITIONAL INFORMATION BELOW *

Forescout Technologies, Inc. (NASDAQ:FSCT)

FSCT Lawsuit on behalf of: investors who purchased February 7, 2019 - October 9, 2019
Lead Plaintiff Deadline : March 2, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/forescout-technologies-inc-loss-form?prid=5501&wire=1

According to the filed complaint, during the class period, Forescout Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Forescout was experiencing significant volatility with respect to large deals and issues related to the timing and execution of deals in the Company's pipeline, especially in Europe, the Middle East, and Africa; (ii) the foregoing was reasonably likely to have a material negative impact on the Company's financial results; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Geron Corporation (NASDAQ:GERN)

GERN Lawsuit on behalf of: investors who purchased March 19, 2018 - September 26, 2018
Lead Plaintiff Deadline : March 23, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/geron-corporation-et-al-loss-form?prid=5501&wire=1

The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.

Westpac Banking Corporation (NYSE:WBK)

WBK Lawsuit on behalf of: investors who purchased November 11, 2015 - November 19, 2019
Lead Plaintiff Deadline : March 30, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/westpac-banking-corporation-loss-form?prid=5501&wire=1

According to the filed complaint, during the class period, Westpac Banking Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) contrary to Australian law, the Company failed to report over 19.5 million international funds transfer instructions to the Australian Transaction Reports and Analysis Centre ("AUSTRAC"); (2) the Company did not appropriately monitor and assess the ongoing money laundering and terrorism financing risks associated with movement of money into and out of Australia; (3) the Westpac did not pass on requisite information about the source of funds to other banks in the transfer chain; (4) despite being aware of the heightened risks, the Company did not carry out appropriate due diligence on transactions in South East Asia and the Philippines that had known financial indicators relating to child exploitation risks; (5) the Company's Anti-Money Laundering and Counter-Terrorism Financing Policy Program was inadequate to identify, mitigate and manage money laundering and terrorism financing risks; and (6) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP